These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16035472)

  • 1. Quality of life in patients on dialysis: benefits of maintaining a hemoglobin of 11 to 12 g/dL.
    Gregory N
    Nephrol Nurs J; 2005; 32(3):307-10. PubMed ID: 16035472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of higher hemoglobin levels on health-related quality of life parameters.
    Gregory N
    Nephrol Nurs J; 2003 Feb; 30(1):75-8. PubMed ID: 12674955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timely correction of anemia at the initiation of dialysis. Case study of the anemic patient.
    Breiterman-White R
    Nephrol Nurs J; 2002 Oct; 29(5):469-72. PubMed ID: 12434453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
    Lefebvre P; Vekeman F; Sarokhan B; Enny C; Provenzano R; Cremieux PY
    Curr Med Res Opin; 2006 Oct; 22(10):1929-37. PubMed ID: 17022852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anemia management practices in peritoneal dialysis patients. Case study of the anemic patient.
    MacCracken MA
    Nephrol Nurs J; 2001 Aug; 28(4):435-8. PubMed ID: 12143466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyporesponse to Epoetin alfa: patients at risk. Case study of the anemic patient.
    Deziel SM
    Nephrol Nurs J; 2002 Feb; 29(1):60-3. PubMed ID: 11887489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B; Semiglazov V; Pawlicki M; Pienkowski T; Tjulandin S; Manikhas G; Makhson A; Roth A; Dodwell D; Baselga J; Biakhov M; Valuckas K; Voznyi E; Liu X; Vercammen E
    J Clin Oncol; 2005 Sep; 23(25):5960-72. PubMed ID: 16087945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between hemoglobin and hematocrit levels and hospitalization and survival rates in dialysis patients.
    Brattich M
    Nephrol Nurs J; 2003 Apr; 30(2):231-4. PubMed ID: 12737001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional ability of patients on dialysis: the critical role of anemia.
    Breiterman-White R
    Nephrol Nurs J; 2005; 32(1):79-82. PubMed ID: 15787087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing the anemia of end-stage renal disease after hospitalization.
    Krishnan M; Adams E
    Nephrol Nurs J; 2004; 31(5):541-4. PubMed ID: 15518256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisions in the prescribing information for Epoetin alfa: implications for nephrology nurses and patients on dialysis.
    Hayslip D
    Nephrol Nurs J; 2008; 35(2):163-7. PubMed ID: 18472685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attaining target hemoglobin levels in patients new to dialysis: individualizing therapy based on initial hemoglobin levels.
    Gregory N
    Nephrol Nurs J; 2004; 31(6):672-5. PubMed ID: 15686331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy.
    Iconomou G; Koutras A; Karaivazoglou K; Kalliolias GD; Assimakopoulos K; Argyriou AA; Ifanti A; Kalofonos HP
    Eur J Cancer Care (Engl); 2008 Nov; 17(6):535-41. PubMed ID: 18707621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.